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Abstract
Background:  Urinary  tract  infections  are  a  leading  cause  of  medical  consultations  in  Mexico  and
the growth  of  antimicrobial  resistance  results  in  increased  morbidity  and  rising  costs.
Aim: To  make  an  economic  evaluation  of  ceftibuten  as  treatment  for  uncomplicated  urinary
tract infections  in  adults,  from  the  perspective  of  the  Mexican  private  health  system.
Methods:  A  cohort-based  decision-making  model  was  developed  to  compare  ceftibuten  with
TMP-SMX,  ciproﬂoxacin,  and  cefalexin.  Effectiveness  was  measured  using  local  susceptibility
rates of  Escherichia  coli.  Costs  were  obtained  from  ofﬁcial  market  value  data  and  converted  to
2014 USD  values.  Incremental  analysis  was  employed  to  determine  if  ceftibuten  was  a  worth-
while investment  on  the  part  of  the  private  health  system  in  Mexico.
Results:  The  total  expected  cost  per  patient  for  ciproﬂoxacin  was  $116  USD  and  the  correspond-
ing costs  for  TMP/SMX  and  cefalexin  were  $92.40  USD  and  $74.80  USD,  respectively.  Ceftibuten
had a  lower  expected  cost  ($34.50  USD)  and  a  higher  percentage  of  therapeutic  success  (99.4%),
compared  with  ciproﬂoxacin  21%,  cefalexin  41%,  and  TMP/SMX  31.7%.
Conclusions:  Even  though  ceftibuten  has  a  higher  market  price  than  other  antimicrobials  in
Mexico, it  can  represent  possible  savings  by  avoiding  the  costs  associated  with  undesirable
results due  to  antimicrobial  resistance  to  E.  coli.
© 2015  Sociedad  Mexicana  de  Urología.  Published  by  Masson  Doyma  México  S.A.  This  is  an
open access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/
by-nc-nd/4.0/).∗ Corresponding author at: Dr. Márquez 162, Colonia Doctores, México CP 06720, DF, Mexico. Tel.: +52 55 55885333.
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007-4085/© 2015 Sociedad Mexicana de Urología. Published by Masson Doyma México S.A. This is an open access article under the CC
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Evaluación  económica  del  ceftibuteno  en  el  tratamiento  de  infecciones  no
complicadas  urinarias  en  pacientes  adultos  mexicanos
Resumen
Antecedentes:  Las  infecciones  urinarias  son  una  causa  principal  de  consultas  médicas  en  México.
La resistencia  antimicrobiana  creciente  incrementa  la  morbilidad  y  los  costos.
Objetivo:  Realizar  una  evaluación  económica  del  ceftibuteno  como  tratamiento  de  infecciones
urinarias  no  complicadas  en  adultos  desde  la  perspectiva  del  sistema  de  salud  privado  en  México.
Material y  métodos: Cohorte  de  modelo  de  decisión  comparando  ceftibuteno  con  TMP-SMX,
ciproﬂoxacina  y  cefalexina.  Medición  de  efectividad  usando  rangos  de  susceptibilidad  locales
para Escherichia  coli. Costos  obtenidos  de  datos  oﬁciales  de  valores  de  mercado  y  convertidos
en valores  en  dólares  americanos  en  2014.  Análisis  incremental  utilizado  para  determinar  la
inversión en  ceftibuteno  desde  la  perspectiva  del  sistema  de  salud  privado  en  México.
Resultados:  Los  costos  totales  por  paciente  con  ciproﬂoxacina  fueron  US$116  mientras  que  los
costos correspondientes  con  TMP/SMX  y  cefalexina  fueron  US$92.4  y  US$74.8  respectivamente.
El ceftibuteno  resultó  con  valor  más  bajo  (US$34.50)  y  un  alto  porcentaje  de  éxito  terapéutico
(99.4%) comparado  con  ciproﬂoxacina  (21%);  cefalexina  (41%)  y  TMP/SMX  (31.7%).
Conclusiones:  El  ceftibuteno  aun  teniendo  el  valor  más  alto  por  unidad  en  México  provee
de posibilidad  de  obtener  ahorros  evitando  costos  asociados  a  resultados  indeseables  por  la
resistencia  antimicrobiana  de  Escherichia  coli.
© 2015  Sociedad  Mexicana  de  Urología.  Publicado  por  Masson  Doyma  México  S.A.  Este  es  un
artículo Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
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mIntroduction
Urinary  tract  infections  (UTIs)  are  one  of  the  leading  causes
of  medical  consultations  by  adults  in  Mexico,  especially  in
sexually  active  women.1 The  incidence  of  UTIs  has  increased
more  than  500%  in  Mexico,  becoming  a  public  health  problem
that  has  put  pressure  on  the  national  healthcare  system.1 A
report  published  by  the  Mexican  Epidemiology  Surveillance
System  revealed  a  rising  incidence  of  UTIs  from  2004  to  2010.
The  age  group  of  25--44  years  was  the  most  affected  with
1,090,886  cases,  followed  by  the  group  of  50--59  years  of
age  with  386,584  cases.  There  were  345,152  cases  reported
for  the  population  65  years  of  age  and  older.1
Common  symptoms  of  cystitis  are  dysuria,  urinary  fre-
quency  and/or  pollakiuria,2 but  inappropriate  management
can  result  in  the  complication  of  pyelonephritis.  The  impact
of  UTIs  on  patient  work  activities  and  quality  of  life  makes
them  a  matter  of  public  health.3
UTI treatment
Antimicrobial  therapy  is  central  in  UTI  management  and
essential  for  preventing  the  involvement  of  the  renal
parenchyma.4 Choosing  antibiotics  entails  factors  that  must
be  considered,  such  as  their  in  vitro  activity  against  the
most  prevalent  uropathogens,  urinary  concentrations  of
the  chosen  antibiotics,  the  possibility  of  sub-optimal  con-
centrations,  effects  of  the  antibiotic  on  the  vaginal  and
gastrointestinal  ﬂora,  adverse  events,  and  the  cost  of  the
therapy.
Most  antibiotics  reach  high  concentrations  in  urine,
above  the  minimum  inhibitory  concentration  for
ﬂ
H
t
common  uropathogens,  which  will  inﬂuence  treatment
ffectiveness.5
atterns of antimicrobial resistance
ntimicrobial  resistance  is  a  growing  global  concern  because
f  increased  morbidity  and  mortality,  and  the  conse-
uent  rising  cost.  It  is  a  multifactorial  phenomenon  caused
y  the  unnecessary  use  of  antibiotics  and  treatment
iscontinuation.6
In  Mexico,  Escherichia  coli  is  the  most  prevalent  bacteria
n  ambulatory  patients,  causing  70--95%  of  the  cases,  fol-
owed  by  Staphylococcus  saprophyticus  (5--20%),  Klebsiella
neumoniae  and  Proteus  mirabilis  (5--20%).7
Studies  published  over  the  last  decade  have  reported  pat-
erns  of  in  vitro  bacterial  resistance  of  E.  coli  strains  to
moxicillin-clavulanate,  ampicillin-sulbactam,  cefuroxime,
rimethoprim  sulfamethoxazole  (TMP-SMX),  and  ﬂuoro-
uinolones.  This  resistance  pattern  involves  most  of  the  oral
ntimicrobials  available  in  Mexico,  limiting  treatment  to
mbulatory  UTI  patients.7,8 Other  studies  have  found  that
MP-SMX  administered  3--6  months  prior  to  the  occurrence
f  a  new  UTI  increases  the  risk  of  antibacterial  resistance
.5-  to  5-fold,  similar  to  the  risk  of  other  factors  such  as
ecent  hospitalization  and  diabetes.9,10
Within  the  framework  of  these  rates  of  antimicrobial
esistance,  recent  studies  have  shown  that  the  percentage
f  resistance  of  E.  coli  to  TMP-SMX  in  a  given  com-
unity  is  greater  than  22%  and  empirical  therapy  with
uoroquinolones  would  be  less  expensive  than  TMP-SMX.
owever,  resistance  to  ﬂuoroquinolones  has  increased  in
he  last  decade  in  other  countries.11 A speciﬁc  con-
ern  for  the  present  authors  is  that  the  Mexican  Clinical
1 A.  Reyes-López,  V.  Blandón-Vijil
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Table  1  Clinical  parameters  used  in  the  decision  model.
Clinical  parameters  Values
Basal  Variationc
E.  coli  susceptibility
Ceftibuten  99.36%a 94.39--100%
Cefalexin  41%a 38.9--43%
Ciproﬂoxacin  21%a 19.9--22%
TMP/SMX  31.7%a 30.11--33.28%
Other parameters
Pyelonephritis  risk 0.05b 0.045--0.055
Hospitalization  risk 0.20b 0.18--0.22
% Antibiotic  switch  for
persistent  infection
75%b 67.5--82.5%
a Barriga et al.17
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uidelines  include  ﬂuoroquinolones  for  UTI  treatment.1
mpirical  treatment  with  TMP-SMX  and/or  ﬂuoroquinolones
ould  cause  50--60%  in  vitro  antimicrobial  resistance  with  a
reat  potential  for  clinical  failure.12
Treatment  duration  has  been  another  concern  in  relation
o  antimicrobial  coverage  in  UTIs.  For  example,  TMP-SMX
reatment  has  been  recommended  for  a  3-day  period  in  some
tudies,  but  it  would  be  unhelpful  due  to  the  high  level  of
acterial  resistance.13,16
The  antimicrobial  activity  of  ceftibuten14 was  originally
etermined  for  a  wide  variety  of  bacterial  species  selected
or  their  resistance  to  oral  and  parenteral  -lactam  antibi-
tics.  Ceftibuten  turned  out  to  be  an  active  -lactam
ntibiotic  against  Enterobacteriaceae  strains  because  it
nhibits  81.6%  of  the  strains  to  ≤8.0  g/mL,  compared  with
5%  and  54.8%  of  the  strains  inhibited  by  ceﬁxime  and
efuroxime,  respectively.
A  study  in  a  Mexican  population  on  in  vitro  antimicrobial
usceptibility  of  gram  negative  microorganisms  related  to
TI  showed  that  ceftibuten  and  netilmicin  had  the  great-
st  activity  against  E.  coli, Klebsiella  spp.,  Proteus  spp.,
erratia  spp.,  Morganella  morganii,  Enterobacter, and  Cit-
obacter  spp.  Antimicrobials  with  the  lowest  activity  were
MP-SMX,  ciproﬂoxacin,  amikacin,  and  levoﬂoxacin.15
conomic impact of antimicrobial resistance
he  irrational  use  of  antibiotics  threatens  public  health
afety  because  of  an  increased  rate  of  drug  resistance.
efore  2008,  only  15%  of  the  treatments  in  Mexico  involved
he  prescription  of  antibiotics  by  a  physician  and  it  was  a
nown  fact  that  around  80%  of  the  prescriptions  were  given
ut  by  pharmacy  employees.16
Since  2008,  the  Mexican  health  authorities  highlighted
he  problem  of  antimicrobial  resistance,  regulating  the
ntibiotic  markets  by  making  the  purchase  of  antibiotics
ossible  only  when  prescribed  by  a  physician.16
Antimicrobial  resistance  translates  into  substantial  ﬁnan-
ial  burden  for  the  healthcare  system,  as  well  as  signiﬁcant
orbidity  for  the  patients.16 Ceftibuten  is  a  good  option
or  the  treatment  of  UTIs  due  to  its  lack  of  resistance.  On
he  other  hand,  it  has  a  higher  market  price,  compared
ith  other  options,  making  it  necessary  to  assess  its  cost-
ffectiveness.  Thus,  the  aim  of  this  study  was  to  perform
n  economic  evaluation  of  ceftibuten  for  the  treatment  of
ncomplicated  UTIs  in  adults,  from  the  perspective  of  the
rivate  healthcare  system  in  Mexico.
ethods
tudy  design
his  study  was  conducted  following  the  international  Good
esearch  Practices  recommendations  for  cost-effectiveness
nalysis  in  healthcare.17 The  analysis  was  developed  sim-
lating  a  hypothetical  cohort  of  adult  men  and  women
ith  uncomplicated  UTI  belonging  to  the  Mexican  private
ealthcare  system.  Four  treatment  strategies  were  con-
idered  for  the  management  of  uncomplicated  UTIs  in  an
utpatient  setting  according  to  relevant  options  for  decision
akers  in  private  local  markets:  (1)  TMP-SMX  160/800  mg;
m
t
u
tb Le and Miller.18
c ±5% from basal value.
2)  ciproﬂoxacin  500  mg;  (3)  cefalexin  500  mg,  and  (4)
eftibuten  400  mg.  Treatment  duration  was  decided  by  the
uthors  according  to  drug  presentations,  which  were  a  box
ith  14  tablets  (1  BID  for  7  days),  a  box  with  12  cap-
ules  (1  BID  for  6  days),  a  box  with  20  tablets  (1  BID  for
0  days),  and  a  box  with  5  capsules  (1  QD  for  5  days),
espectively.
tudy  setting  and  population
t  was  assumed  that  once  a  diagnosis  of  uncomplicated  UTI
as  made,  outpatient  therapy  with  the  mentioned  antimi-
robials  would  be  considered,  and  one  of  the  therapeutic
ptions  must  be  chosen.  Since  E.  coli  is  the  main  causal
gent  of  UTIs  (>80%)  in  the  Mexican  population,  it  was
ssumed  that  the  therapeutic  response  of  the  antibiotics
nder  comparison  was  a  function  of  E.  coli  susceptibility
o  them.  Susceptibility  rates  of  E.  coli  to  different  antimi-
robials  reported  by  Barriga  et  al.15 were  used  to  model
he  expected  UTI  resolution  or  the  persistence  of  UTI  symp-
oms.  That  trial  included  1200  bacterial  isolations  obtained
equentially  during  six  months  from  adult  outpatients  with
linical  symptoms  of  uncomplicated  UTI  and  positive  urine
ulture,  having  received  ambulatory  care.  Table  1  shows  all
he  clinical  parameters  used  in  the  model  and  the  corre-
ponding  data  sources.18
ecision  model
e  developed  a  decision  tree  model  (Fig.  1) to  simu-
ate  possible  outcomes  of  uncomplicated  UTI  treated  either
ith  TMP-SMX,  ciproﬂoxacin,  cefalexin,  or  ceftibuten,  based
n  a  model  previously  published  by  Le  and  Miller.18 We
odeled  the  following  clinical  outcomes:  UTI  resolution  or
ersistent  UTI  symptoms.  Unresolved  UTI  could  derive  into
yelonephritis  requiring  either  inpatient  or  outpatient  treat-
ent,  or  only  persistent  infection  which  could  give  rise  to
wo  possible  situations:  extended  treatment  according  to
rine  culture  or  an  empirical  antibiotic  switch.  Successful
reatment  meant  that  a patient  was  clinically  cured.  A  time
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Ceftibuten
Cefalexine
Persistent UTI symptoms
UTI resolution
Pyelonephritis
Inpatient treatment
Empirical antibiotic switch
Outpatient treatment
Extended treatment course until
culture results returned
Persistent infection
Ciprofloxacine
TMP/SMX
Uncomplicated UTI
Adult patients
sed  for  the  economic  evaluation  of  ceftibuten.
Table  2  Costs  data  used  in  the  decision  model.
Economic  parameters  Values
Basal  Variation
Mean  prices  (US$)  of
antimicrobials  under
comparison
Standard  deviation
Ceftibuten  33.76  4.82
Cefalexin  5.19  1.19
Ciproﬂoxacin  22.79  2.79
TMP/SMX  11.71  1.22
Other inputs  (USD)  Min--Max
Urine culture  23.53  21.18--25.88
Urinalysis  7.90  5.99--9.81
Blood chemistry  23.65  15.19--32.11
Blood count  17.02  11.18--22.86
Ultrasound  52.61  47.35--57.87
Inpatient  day 132.11 91.87--172.35
ER  visit  76.14  68.53--83.75
Ofﬁce visit  33.71  29.55--37.88
Ceftriaxonea 41.11b 3.22c
a
E
S
o
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BFigure  1  Analytical  decision  tree  model  u
frame  less  than  one  year  was  used  in  the  model,  based  on
the  natural  history  of  disease  in  UTIs.
Model  assumptions
The  model  assumed  that  there  were  no  fatal  events  from
acute  pyelonephritis  following  a  real-life  scenario  and  that
there  were  no  recurrences  of  acute  pyelonephritis  either.
When  patients  were  treated  for  uncomplicated  UTI  with
TMP-SMX,  ciproﬂoxacin,  or  cefalexin,  and  there  was  persis-
tent  infection,  the  antibiotic  was  empirically  switched  to
ceftibuten.  In  turn,  if  infection  persisted  after  the  initial
treatment  with  ceftibuten,  the  change  was  made  to  another
option.
Costs
From  the  perspective  of  the  Mexican  private  healthcare  sys-
tem,  the  data  on  direct  medical  costs  were  collected  and
converted  to  2014  U.S.  dollars  (USD)  (Table  2),  including  the
costs  of  antibiotic  therapies,  laboratory  tests,  ultrasounds,
hospital  stay/day,  emergency  room  (ER)  visits,  and  ofﬁce
visits.  The  costs  of  antibiotic  therapies  were  obtained  from
the  market  wholesale  drug  prices.  The  unit  costs  of  other
medical  inputs  were  obtained  from  the  National  Institute
of  Statistics  and  Geography  (INEGI  for  its  Spanish  acronym)
website.19 The  estimation  of  inpatient  treatment  cost  of
pyelonephritis  was  made  assuming  the  use  of  the  following
resources:  ceftriaxone  IV  2  g  daily  (unit  price:  $41.11  USD;
10-day  treatment:  $822.22  USD),  5  hospital  days  ($660.56
USD),  one  ER  visit  ($76.14  USD),  one  ofﬁce  visit  ($33.71
USD),  and  the  following  tests:  urinalysis,  urine  culture,
chemistry  test,  blood  count,  and  ultrasound  ($124.71  USD).
The  total  cost  of  inpatient  treatment  of  pyelonephritis
was  $1717.35  USD.  The  cost  of  outpatient  treatment  of
pyelonephritis  ($946.93  USD)  was  estimated  using  the  same
amount  of  resources  as  with  the  inpatient  scenario,  except
for  hospital  stay  and  ER  visit.  Costs  were  not  discounted  in
our  analysis  because  the  time  horizon  used  was  less  than  one
year.
T
i
p
eAntimicrobial used for the treatment of pyelonephritis.
b Mean value.
c Standard deviation.
ffectiveness  measure
ince  therapeutic  response  was  based  on  susceptibility  rates
f  E.  coli  to  the  antimicrobials  being  compared,  the  effec-
iveness  measure  modeled  was  the  expected  percentage  of
atients  cured  of  uncomplicated  UTI  with  the  antimicrobials
nalyzed.
ase-case  analysiso  determine  whether  ceftibuten  would  be  a worthwhile
nvestment  for  the  treatment  of  uncomplicated  UTI,  we
erformed  the  standard  incremental  analysis  of  cost-
ffectiveness  ratios  using  spreadsheets.  As  a  decision  rule
14  A.  Reyes-López,  V.  Blandón-Vijil
Table  3  Base-case  results  per  treated  patient.
Options  Total  expected
cost  (USD)
Incremental
cost  (USD)
Expected  %  of
cured  patients
Incremental
cost-effectiveness  ratio
Ceftibuten  34.50  99.4  Dominant
Cefalexin 74.85  40.35  41.0  Dominated
Ciproﬂoxacin  116.06  81.56  21.0  Dominated
t
i
u
t
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a
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s
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a
fTMP/SMX 92.43  57.93  
o  know  if  the  treatment  with  ceftibuten  was  cost-effective
n  relation  to  the  Mexican  private  healthcare  system,  we
sed  the  cost-effectiveness  threshold  of  one  gross  domes-
ic  product  (GDP)  per  capita  per  additional  health  beneﬁt
nit,  which  is  generally  accepted  in  Mexico  by  the  health
uthorities.
ensitivity  analysisn  order  to  embody  the  uncertainty  of  the  parameters
sed  in  the  decision  model,  we  conducted  several  one-way
ensitivity  analyses.  Basal  values  of  clinical  and  economic
a
p
c
c
Ceftibuten E. Coli susceptibility
Risk of pyelonephritis
Ceftibuten price
Cost of office visit
Cefalexine E. Coli susceptibility
Ceftriaxone price
Cefalexine price
Day of stay cost
Risk of hospitalization
Antibiotic switch due to persistent infection
Cost of urine culture test
Cost of blood chemistry test
Cost of blood count test
Cost of ultrasound test
Cost of urinalysis test
Cost of emergency visit
Cefixime price
TMP-SMX price
Risk of pyelonephritis
TMP-SMX E. Coli susceptibility
Ceftibuten price
Cost of office visit
Ceftibuten E. Coli susceptibility
Ceftriaxone price
Day of stay cost
Risk of hospitalization
Antibiotic switch due to persistent infection
Cost of urine culture test
Cost of blood chemistry test
Cost of blood count test
Cost of ultrasound test
Cost of urinalysis test
Cost of emergency visit
Cefixime price
Min
Max
–$44 –$43 –$42 –$41 –$40 –$39 –$38 –$37 –$36 –$35 –$34
–$62 –$61 –$60 –$5
A
C
igure  2  Results  of  univariate  sensitivity  analysis  of  the  econom
nalyses are  shown  by  means  of  tornado  diagrams  formed  by  horizon
act that  parameters  with  high  uncertainty  are  located  at  the  top  of
t the  bottom.  Tornado  A  shows  the  results  for  the  comparison  betwe
or the  comparison  between  ceftibuten  and  ciproﬂoxacin,  and  ceftib31.7  Dominated
arameters  were  varied  throughout  plausible  ranges  as
hown  in  Tables  1  and  2.
esults
ase-case  results
he  total  expected  costs  per  treated  patient  for  each  ther-
peutic  option,  as  well  as  the  expected  percentage  of  cured
atients,  are  shown  together  in  Table  3.  We  can  see  that
eftibuten  exhibits  the  lower  cost  and  also  the  higher  per-
entage  of  therapeutic  success  compared  with  the  rest  of
Ciprofloxacine E. Coli susceptibility
Risk of pyelonephritis
Ceftibuten price
Cost of office visit
Ceftibuten E. Coli susceptibility
Ceftriaxone price
Ciprofloxacine price
Day of stay cost
Risk of hospitalization
Antibiotic switch due to persistent infection
Cost of urine culture test
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 the  diagram,  so  the  parameter  with  less  uncertainty  is  located
en  ceftibuten  and  cefalexin.  Tornados  B  and  C  show  the  results
uten  and  TMP/SMX,  respectively.
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the  antibiotics.  Using  the  jargon  of  pharmacoeconomics,
we  can  state  that  ceftibuten  is  a  ‘dominant’  option  com-
pared  with  other  options,  since  it  is  more  effective  and
less  costly.  Furthermore,  under  a  dominant  scenario  like
that  shown  for  ceftibuten,  decision  makers  do  not  need  any
additional  analysis,  such  as  the  calculation  of  incremental
cost-effectiveness  ratios,  to  know  that  the  dominant  ther-
apy  (ceftibuten)  represents  ‘good  value-for-money’.
Since  ceftibuten  turned  out  to  be  a  dominant  strategy  for
the  treatment  of  uncomplicated  UTI,  the  economic  analy-
sis  must  focus  on  the  expected  savings  per  patient  treated
with  ceftibuten,  instead  of  the  other  three  options.  Com-
parison  between  ceftibuten  and  ciproﬂoxacin  resulted  in  a
higher  savings  per  patient  treated  (Table  3),  followed  by  the
comparison  between  ceftibuten  and  TMP/SMX.
Sensitivity  analysis  results
Given  that  the  relevant  base-case  results  were  focused  on
savings  gained  with  ceftibuten,  hence  the  objective  of  the
one-way  sensitivity  analyses  was  to  assess  the  robustness
of  the  model  in  terms  of  expected  savings.  Fig.  2  shows  a
series  of  tornado  diagrams  represented  by  means  of  hori-
zontal  bars,  from  the  widest  to  the  narrowest,  expressing
different  degrees  of  uncertainty  from  the  parameter  val-
ues  into  the  base-case  results.  We  can  see  that  although
some  parameters  embodied  a  high  degree  of  uncertainty,  the
results  did  not  change  the  dominant  proﬁle  of  ceftibuten.
Discussion
The  pharmacoeconomic  analysis  informs  key  decision  mak-
ers  about  the  economic  bearings  associated  not  only  with
the  price  of  the  drugs,  but  also  with  all  the  relevant  out-
comes  expected  from  the  use  of  either  therapeutic  options.
These  results  enabled  us  to  conclude  that  despite  the  fact
that  ceftibuten  has  the  highest  unit  market  price  in  Mexico,
it  can  still  represent  savings,  when  compared  with  the  other
drugs  analyzed,  by  avoiding  the  costs  associated  with  unde-
sirable  outcomes  caused  by  the  antimicrobial  resistance  of
E.  coli,  the  most  prevalent  causal  agent  of  uncomplicated
UTI  in  Mexico.
In  order  to  aid  the  decision-making  process  with  good  evi-
dence,  the  limitations  of  this  study  should  be  mentioned.
The  bacterial  resistance  data  were  obtained  from  only  one
source  that  analyzed  in  vitro  strains  from  uncomplicated  UTI
patients  from  a  single  healthcare  center  in  Mexico.  In  addi-
tion,  information  about  the  resources  used  was  obtained
from  a  review  of  the  Mexican  Clinical  Guidelines  for  UTI
in  order  to  model  the  usual  treatment  path.  Another  lim-
itation  was  the  simpliﬁcation  of  the  decision  model  under
a  local  frame  of  limited  information,  although  it  was  driven
by  broader  assumptions  in  order  to  facilitate  the  assessment
of  therapies.  However,  the  international  principles  of  good
practice  in  pharmacoeconomic  research  were  always  fol-
lowed  to  enhance  the  transparency  and  reproducibility  of
the  results.Future  research  will  be  needed  to  know  if  the  use
of  ceftibuten  for  the  treatment  of  uncomplicated  UTI  in
the  Mexican  population  will  modify  the  antimicrobial  resis-
tance  patterns  of  E.  coli. This  will  also  have  economicxico  15
onsequences,  since  the  expected  rate  of  therapeutic  suc-
ess  or  failure  under  a  new  environment  of  antimicrobial
esistance  could  represent  a  different  disease  burden  for
he  patients,  healthcare  providers,  and  payers.  For  now,
he  management  of  uncomplicated  UTIs  with  ceftibuten  is  a
ood  value-for-money  from  the  perspective  of  the  patients
irectly  paying  for  the  treatment,  but  also  for  third  party
ayers,  such  as  the  private  insurance  companies.
onclusions
rivate  healthcare  systems  in  Mexico  should  evaluate  cur-
ent  interventions  for  treatment  of  uncomplicated  UTI  that
re  cost-effective  from  the  resistance  perspective.  We
elieve  our  analysis  shows  that  ceftibuten,  previously  not
ully  considered,  could  be  cost-effective.  We  support  the
erformance  of  prospective  new  interventions  that  would
hallenge  and  compare  current  practice  strategies.
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